Page 63 - அமெரிக்கன் சமூகம் ஆஃப் ஹீமாட்டாலஜி News Today : Breaking News, Live Updates & Top Stories | Vimarsana
COVID-19 Vaccines: Safe for Immunocompromised Patients?
medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
Covid-19 Leaves Lasting Impact on Hematology at ASH 2020 Conference
labiotech.eu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from labiotech.eu Daily Mail and Mail on Sunday newspapers.
Following is a transcript of their remarks:
Susan O Brien, MD: Hi, everyone, and welcome to this roundtable where we re going to discuss CLL presentations at ASH 2020 this year. I m Dr. Susan O Brien from the Chao Family Comprehensive Cancer Center at the University of California in Irvine, and I m joined by two esteemed colleagues, Dr. Jennifer Brown from Dana-Farber and Dr. Anthony Mato from Memorial Sloan Kettering.
An interesting presentation at ASH this year that many people were looking forward to was the trial looking at the combination of what s called U2, which is a novel anti-CD20 antibody, ublituximab, combined with a novel PI3K delta inhibitor, umbralisib. In this randomized trial, the comparator arm was obinutuzumab with chlorambucil and it was interesting because the trial actually included both previously untreated as well as previously treated patients. Jennifer, do you want to talk about some of the results from this trial?
Last April, I wrote a letter to my parents, who would have been 104 this year, in the form of an op-ed column in my hometown newspaper in Lancaster, PA. I expressed my hope that, in dealing with the upheaval of the pandemic, we could draw upon the examples they set in coping with the Great Depression as teenagers (without cell phones) and enduring World War II as young parents (without Internet access).
In closing, I promised to write again “to let you know that we rose to the occasion, came together (in mind, if not in body), rode out the COVID-19 storm… in our virtual tornado cellars, and minimized the amount of human suffering.”
Chimeric antigen receptor (CAR)-modified cytokine induced killer cell (CAR-CIK) technology featured at ASH
DURHAM, N.C., Dec. 16, 2020 (GLOBE NEWSWIRE) CoImmune, Inc. today announced that its CAR-CIK technology was featured at the annual American Society of Hematology (ASH) meeting with an interim update on the phase 1/2 dose escalation clinical trial in B-cell acute lymphoblastic leukemia (B-ALL). The trial is being conducted at Ospedale San Gerardo, Monza, Italy by principal investigator Andrea Biondi, M.D. and at Papa Giovanni XXIII, Bergamo, Italy by principal investigator Alessandro Rambaldi, M.D. The presentation on was on December 7
th during the immunotherapy session and was given by Dr. Chiara Magnani of the Tettamanti Research Center, Monza, Italy.
vimarsana © 2020. All Rights Reserved.